FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2294693110> ?p ?o ?g. }

• W2294693110 endingPage "e182" @default.
• W2294693110 startingPage "e175" @default.
• W2294693110 abstract "Background Studies of Malawi's option B+ programme for HIV-positive pregnant and breastfeeding women have reported high loss to follow-up during pregnancy and at the start of antiretroviral therapy (ART), but few data exist about retention during breastfeeding and after weaning. We examined loss to follow-up and retention in care in patients in the option B+ programme during their first 3 years on ART. Methods We analysed two data sources: aggregated facility-level data about patients in option B+ who started ART between Oct 1, 2011, and June 30, 2012, at 546 health facilities; and patient-level data from 20 large facilities with electronic medical record system for HIV-positive women who started ART between Sept 1, 2011, and Dec 31, 2013, under option B+ or because they had WHO clinical stages 3 or 4 disease or had CD4 counts of less than 350 cells per μL. We used facility-level data to calculate representative estimates of retention and loss to follow-up. We used patient-level data to study temporal trends in retention, timing of loss to follow-up, and predictors of no follow-up and loss to follow-up. We defined patients who were more than 60 days late for their first follow-up visit as having no follow-up and patients who were more than 60 days late for a subsequent visit as being lost to follow-up. We calculated proportions and cumulative probabilities of patients who had died, stopped ART, had no follow-up, were lost to follow-up, or were retained alive on ART for 36 months. We calculated odds ratios and hazard ratios to examine predictors of no follow-up and loss to follow-up. Findings Analysis of facility-level data about patients in option B+ who had not transferred to a different facility showed retention in care to be 76·8% (20 475 of 26 658 patients) after 12 months, 70·8% (18 306 of 25 849 patients) after 24 months, and 69·7% (17 787 of 25 535 patients) after 36 months. Patient-level data included 29 145 patients. 14 630 (50·2%) began treatment under option B+. Patients in option B+ had a higher risk of having no follow-up and, for the first 2 years of ART, higher risk of loss to follow-up than did patients who started ART because they had CD4 counts less than 350 cells per μL or WHO clinical stage 3 or 4 disease. Risk of loss to follow-up during the third year was low and similar for patients retained for 2 years. Retention rates did not change as the option B+ programme matured. Interpretation Our data suggest that pregnant and breastfeeding women who start ART immediately after they are diagnosed with HIV can be retained on ART through the option B+ programme, even after many have stopped breastfeeding. Interventions might be needed to improve retention in the first year on ART in option B+. Funding Bill & Melinda Gates Foundation, Partnerships for Enhanced Engagement in Research Health, and National Institute of Allergy and Infectious Diseases." @default.
• W2294693110 created "2016-06-24" @default.
• W2294693110 creator A5009025550 @default.
• W2294693110 creator A5010630492 @default.
• W2294693110 creator A5011657274 @default.
• W2294693110 creator A5020104507 @default.
• W2294693110 creator A5029141089 @default.
• W2294693110 creator A5038936446 @default.
• W2294693110 creator A5059561147 @default.
• W2294693110 creator A5072414745 @default.
• W2294693110 creator A5078288435 @default.
• W2294693110 creator A5084614651 @default.
• W2294693110 date "2016-04-01" @default.
• W2294693110 modified "2023-09-29" @default.
• W2294693110 title "Retention in care during the first 3 years of antiretroviral therapy for women in Malawi's option B+ programme: an observational cohort study" @default.
• W2294693110 cites W1751991607 @default.
• W2294693110 cites W1964679050 @default.
• W2294693110 cites W1973617793 @default.
• W2294693110 cites W1981571008 @default.
• W2294693110 cites W1987152376 @default.
• W2294693110 cites W2011058830 @default.
• W2294693110 cites W2013225087 @default.
• W2294693110 cites W2029384044 @default.
• W2294693110 cites W2038981426 @default.
• W2294693110 cites W2039836366 @default.
• W2294693110 cites W2044285984 @default.
• W2294693110 cites W2066534928 @default.
• W2294693110 cites W2067590616 @default.
• W2294693110 cites W2083484297 @default.
• W2294693110 cites W2100815001 @default.
• W2294693110 cites W2119957662 @default.
• W2294693110 cites W2136845149 @default.
• W2294693110 cites W2138342325 @default.
• W2294693110 cites W2152505869 @default.
• W2294693110 cites W2166403078 @default.
• W2294693110 cites W2238552371 @default.
• W2294693110 cites W2403671454 @default.
• W2294693110 cites W4210821386 @default.
• W2294693110 doi "https://doi.org/10.1016/s2352-3018(16)00008-4" @default.
• W2294693110 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4904064" @default.
• W2294693110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27036993" @default.
• W2294693110 hasPublicationYear "2016" @default.
• W2294693110 type Work @default.
• W2294693110 sameAs 2294693110 @default.
• W2294693110 citedByCount "151" @default.
• W2294693110 countsByYear W22946931102014 @default.
• W2294693110 countsByYear W22946931102016 @default.
• W2294693110 countsByYear W22946931102017 @default.
• W2294693110 countsByYear W22946931102018 @default.
• W2294693110 countsByYear W22946931102019 @default.
• W2294693110 countsByYear W22946931102020 @default.
• W2294693110 countsByYear W22946931102021 @default.
• W2294693110 countsByYear W22946931102022 @default.
• W2294693110 countsByYear W22946931102023 @default.
• W2294693110 crossrefType "journal-article" @default.
• W2294693110 hasAuthorship W2294693110A5009025550 @default.
• W2294693110 hasAuthorship W2294693110A5010630492 @default.
• W2294693110 hasAuthorship W2294693110A5011657274 @default.
• W2294693110 hasAuthorship W2294693110A5020104507 @default.
• W2294693110 hasAuthorship W2294693110A5029141089 @default.
• W2294693110 hasAuthorship W2294693110A5038936446 @default.
• W2294693110 hasAuthorship W2294693110A5059561147 @default.
• W2294693110 hasAuthorship W2294693110A5072414745 @default.
• W2294693110 hasAuthorship W2294693110A5078288435 @default.
• W2294693110 hasAuthorship W2294693110A5084614651 @default.
• W2294693110 hasBestOaLocation W22946931101 @default.
• W2294693110 hasConcept C126322002 @default.
• W2294693110 hasConcept C131872663 @default.
• W2294693110 hasConcept C141071460 @default.
• W2294693110 hasConcept C142462285 @default.
• W2294693110 hasConcept C144024400 @default.
• W2294693110 hasConcept C149923435 @default.
• W2294693110 hasConcept C167135981 @default.
• W2294693110 hasConcept C187212893 @default.
• W2294693110 hasConcept C201903717 @default.
• W2294693110 hasConcept C23131810 @default.
• W2294693110 hasConcept C2776283161 @default.
• W2294693110 hasConcept C2777215511 @default.
• W2294693110 hasConcept C2779234561 @default.
• W2294693110 hasConcept C2993143319 @default.
• W2294693110 hasConcept C3013748606 @default.
• W2294693110 hasConcept C512399662 @default.
• W2294693110 hasConcept C54355233 @default.
• W2294693110 hasConcept C71924100 @default.
• W2294693110 hasConcept C72563966 @default.
• W2294693110 hasConcept C86803240 @default.
• W2294693110 hasConceptScore W2294693110C126322002 @default.
• W2294693110 hasConceptScore W2294693110C131872663 @default.
• W2294693110 hasConceptScore W2294693110C141071460 @default.
• W2294693110 hasConceptScore W2294693110C142462285 @default.
• W2294693110 hasConceptScore W2294693110C144024400 @default.
• W2294693110 hasConceptScore W2294693110C149923435 @default.
• W2294693110 hasConceptScore W2294693110C167135981 @default.
• W2294693110 hasConceptScore W2294693110C187212893 @default.
• W2294693110 hasConceptScore W2294693110C201903717 @default.
• W2294693110 hasConceptScore W2294693110C23131810 @default.
• W2294693110 hasConceptScore W2294693110C2776283161 @default.
• W2294693110 hasConceptScore W2294693110C2777215511 @default.

• next